* MEI Pharma Inc is expected to show a fall in quarterly revenue when it reports results on May 9 (estimated) for the period ending March 31 2024
* The San Diego California-based company is expected to report a 99.4% decrease in revenue to $37.5 thousand from $5.89 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
* LSEG's mean analyst estimate for MEI Pharma Inc is for a loss of $1.52 per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for MEI Pharma Inc is $20.00, above its last closing price of $3.20.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -1.33 -1.32 -1.66 Missed -25.3
Sep. 30 2023 -2.12 -2.12 8.46 Beat 499.1
Jun. 30 2023 -2.41 -1.51 Beat 37.5
Mar. 31 2023 -2.78 -2.87 -2.32 Beat 19.1
Dec. -3.03 -3.00 1.60 Beat 153.3
31 2022
Sep. 30 2022 -2.86 -2.87 -2.40 Beat 16.3
Jun. 30 2022 -3.55 -3.71 -2.40 Beat 35.4
Mar. 31 2022 -3.53 -3.65 -1.40 Beat 61.6
This summary was machine generated May 7 at 11:24 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments